EYEGENE Inc.

전체메뉴닫기

R & D

Herpes Zoster Vaccine

Herpes Zoster Overview

  • Varicella Zoster Virus (VZV) is one of eight herpesviruses known to infect humans. It causes chickenpox (varicella), a disease most commonly affecting children, teens, and young adults, and herpes zoster (shingles) in older adults.
  • Each year, VZV affects 500,000 persons in the U.S. and 10 million people worldwide. In about 10-20% of cases, VZV reactivates later in life within a person’s body, producing a disease known as herpes zoster or shingles. The incidence of herpes zoster is 1.5 to 3.0 cases per 1,000 persons, and is estimated to occur in up to 20% of individuals during their lifetime. The incidence of herpes zoster in the case of 65 years older is 3.9~11.8 people per year per 1,000 people.

Herpes Zoster Stages

  • After the chickenpox infection caused by Varicella zoster virus is over, the virus may remain inactive in nervous system
  • It reactivates by poor immune function, the main symptom is painful skin rash with blister in a entire body or localized area
  • Facial nerve palsy caused by penetration around the face & meningitis caused by penetrating cranial nerve
  • Risk of incidence of intractable pain disease called postherpetic neuralgia(PHN) after treatment

EG-HZ Highlights

Clinical Trial Status

  • Government
    Grant (MOHW
    2.7bn. KRW)

    2014

  • Cell Line
    Development
    Adjuvant Screening

    2015

  • MCB Production
    Process development

    2016~2017

  • Pre-Clinical

    2018

  • Phase 1 approval

    2019.12

  • Phase 1 Completed

    2021.06

  • Licensing agreement with BMI Korea

    2022

  • T. +82-2-322-1687
  • F. +82-2-302-4359 / +82-2-324-8059
  • 본사 : [07528] 서울특별시 강서구 양천로 401 강서한강자이타워 B동 1211호
  • 연구소 : [10551] 경기도 고양시 덕양구 의장로 122-1 2층